27th PORTO CANCER MEETING
Stemness & Metastasis: Advances in Research and Clinical Translation
20-21 May 2021

Anna Dubrovska

Faculty of Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany

Position:

W2 Professor, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany;

Group leader “Biomarkers for the Individualized Radiotherapy”, OncoRay – National Center for Radiation Research in Oncology, Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology – OncoRay, Germany

Institution:

OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany; Helmholtz-Zentrum Dresden – Rossendorf, Institute of Radiooncology – OncoRay, Dresden, Germany; German Cancer Consortium (DKTK), Partner site Dresden, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany

Positions and Employment:

2003-2007: Postdoctoral Fellow, Ludwig Institute for Cancer Research, Uppsala, Sweden;

2007-2011: Visiting scientist, Genomics Institute of the Novartis Research Foundation, San Diego, USA;

2007-2011: Research Associate, The Scripps Research Institute, La Jolla, USA;

2011-2016: W2 Professor, group leader “Biomarkers for the Individualized Radiotherapy”, OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany;

Since 2016: Tenured W2 Professor, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany. Group leader “Biomarkers for the Individualized Radiotherapy”, OncoRay – National Center for Radiation Research in Oncology, Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology – OncoRay, Germany.

Education:

1993 – 1998 BSc (Biology) with Honors Degree, Kyiv National University, Ukraine.

1997 – 1998 MSc (Genetics) with Honors Degree, Kyiv National University, Ukraine.

1998 – 2003 PhD in Genetics, Institute of Molecular Biology and Genetics, Kyiv, Ukraine.

5 Representative papers:

Digomann D, et al, Dubrovska A*. The CD98 Heavy Chain Is a Marker and Regulator of Head and Neck Squamous Cell Carcinoma Radiosensitivity. Clin Cancer Res. 2019; 25(10):3152-3163.

Krause M, Dubrovska A, Linge A, Baumann M. Cancer Stem Cells: radioresistance, prediction of radiotherapy outcome and specific targets for combined treatments. Advanced Drug Delivery Reviews, 2017, 109:63-73.

Peitzsch C, et al. Dubrovska A*. An epigenetic reprogramming strategy to resensitize radioresistant prostate cancer cells. Cancer Res. 2016, 76(9):2637-51.

Cojoc M, et al. Dubrovska A*. Aldehyde Dehydrogenase Is Regulated by β-Catenin/TCF and Promotes Radioresistance in Prostate Cancer Progenitor Cells. Cancer Res. 2015 Apr 1;75(7):1482-94.

Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, García-Echeverría C, Schultz PG, Reddy VA. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci U S A. 2009, 106(1):268-73.